68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical persitence after radical prostatectomy. Detection of cancer locations and impact on subsequent therapy.

Conclusions: In this patient-series, 68Ga-PSMA-11 PET/CT proved its role in BCP setting detecting disease outside prostate bed in 47.6% of cases. In these patients adjuvant/salvage therapy plan was modified due to the integration of 68Ga-PSMA-11 PET/CT results into the decision-making process. These data may suggest the presence of extended disease not detected by conventional imaging prior to surgery and highlight the importance of PET imaging in BCP setting.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Ceci, F., Nicolotti, D. G., Passera, R., Pilati, E., Guarneri, A., Bartoncini, S., Lillaz, B., Zitella, A., Gontero, P., Ricardi, U., Bisi, G., Deandreis, D. Tags: Prostate/GU Imaging Posters Source Type: research